Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974303 | 0.88 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL8974500 | 0.87 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL8974455 | 0.87 | PTGS2 (0.55) | PTGS2PTGS1KIF11 | |
| SCHEMBL9116379 | 0.76 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL12341698 | 0.74 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL8973922 | 0.74 | PTGS2 (0.66) | PTGS2PTGS1 | |
| SCHEMBL8974161 | 0.74 | PTGS2 (0.57) | PTGS2PTGS1KIF11 | |
| SCHEMBL8975150 | 0.73 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL8974655 | 0.73 | PTGS2 (0.56) | PTGS2PTGS1KIF11 | |
| SCHEMBL12807 | 0.72 | GAA (0.65) | PTGS2PTGS1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5576339-A | Pyridyl substituted cyclopentadienes for the treatment of inflamation | HUANG HORNG-CHIH (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1995030656-A1 | SUBSTITUTED CYCLOPENTADIENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-11-16 | — | — | WO | disclosed |
| US-5418254-A | Side effect reduction | G. D. SEARLE & CO. (US) | 1995-05-23 | — | — | US | disclosed |